Revance Therapeutics (RVNC) News Today $3.09 +0.02 (+0.65%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Revance Therapeutics, Inc. (NASDAQ:RVNC) Shares Sold by Franklin Resources Inc.Franklin Resources Inc. cut its position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) by 23.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,784,658 shares ofDecember 20 at 4:51 AM | marketbeat.comRevance Therapeutics (NASDAQ:RVNC) Now Covered by StockNews.comStockNews.com started coverage on Revance Therapeutics in a research report on Friday. They issued a "hold" rating for the company.December 20 at 2:07 AM | marketbeat.comRevance Therapeutics ticks higher as holder says Crown deal undervalues companyDecember 19 at 3:08 PM | msn.comWellington Management Group LLP Acquires Shares of 446,027 Revance Therapeutics, Inc. (NASDAQ:RVNC)Wellington Management Group LLP bought a new position in Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 446,027 shares of the biophaDecember 19 at 3:33 AM | marketbeat.comHighTower Advisors LLC Has $765,000 Stock Position in Revance Therapeutics, Inc. (NASDAQ:RVNC)HighTower Advisors LLC lowered its position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) by 72.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 147,400 shares of the biopharmaceutical cDecember 19 at 3:15 AM | marketbeat.comREVANCE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Revance Therapeutics, Inc. - RVNCDecember 17, 2024 | businesswire.com725,000 Shares in Revance Therapeutics, Inc. (NASDAQ:RVNC) Purchased by Oddo BHF Asset Management SasOddo BHF Asset Management Sas purchased a new position in Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 725,000 shares of the biopharmaceutical compaDecember 13, 2024 | marketbeat.comRevance receives acquisition offer from Crown Laboratories for $3.10 per shareDecember 12, 2024 | markets.businessinsider.comCrown Laboratories Initiates Tender Offer To Buy Revance At $3.10/Share In CashDecember 12, 2024 | markets.businessinsider.comShareholder Alert: Ademi LLP Investigates Whether Revance Therapeutics, Inc. Is Obtaining a Fair Price for Its Public ShareholdersDecember 12, 2024 | businesswire.comCrown Laboratories Commences Friendly Tender Offer for All Outstanding Common Shares of Revance Therapeutics at $3.10 per shareDecember 12, 2024 | prnewswire.comBrokerages Set Revance Therapeutics, Inc. (NASDAQ:RVNC) Price Target at $9.66December 12, 2024 | americanbankingnews.comRevance price target lowered to $3.10 from $6.66 at MizuhoDecember 11, 2024 | markets.businessinsider.comRevance Therapeutics (NASDAQ:RVNC) Price Target Cut to $3.10 by Analysts at MizuhoDecember 11, 2024 | americanbankingnews.comRevance Therapeutics (NASDAQ: RVNC) Enters into Merger Agreement with Crown LaboratoriesOn December 7, 2024, Revance Therapeutics, Inc., a biotechnology company listed on the Nasdaq Global Market under the ticker RVNC, announced that it has signed anDecember 11, 2024 | americanbankingnews.comRevance Therapeutics Sees Unusually Large Options Volume (NASDAQ:RVNC)December 11, 2024 | americanbankingnews.comRevance Therapeutics (NASDAQ:RVNC) Given New $3.10 Price Target at MizuhoMizuho dropped their price objective on shares of Revance Therapeutics from $6.66 to $3.10 and set a "neutral" rating for the company in a report on Tuesday.December 10, 2024 | marketbeat.comCrown Labs Slashes Revance Therapeutics Takeover Price by 53%December 9, 2024 | marketwatch.comRevance agrees to lower take-private offer by Crown LabsDecember 9, 2024 | investing.comCrown Laboratories To Buy Revance For $3.10/Share In Amended And Restated Merger DealDecember 9, 2024 | markets.businessinsider.comRevance Therapeutics plunges after Crown Labs cuts takeover price in halfDecember 9, 2024 | seekingalpha.comRevance Therapeutics once again tries to go private with Crown Laboratories mergerDecember 9, 2024 | bizjournals.comRevance agrees to lower-priced buyout offer by Crown LaboratoriesDecember 9, 2024 | reuters.comCrown Laboratories and Revance Enter into Amended and Restated Merger AgreementDecember 9, 2024 | prnewswire.comRevance Therapeutics, Inc. (NASDAQ:RVNC) Receives Consensus Recommendation of "Hold" from AnalystsRevance Therapeutics, Inc. (NASDAQ:RVNC - Get Free Report) has been given a consensus rating of "Hold" by the nine ratings firms that are presently covering the stock, MarketBeat.com reports. Eight equities research analysts have rated the stock with a hold rating and one has assigned a buy ratinDecember 7, 2024 | marketbeat.comRevance Therapeutics (NASDAQ:RVNC) Coverage Initiated at StockNews.comStockNews.com assumed coverage on shares of Revance Therapeutics in a research report on Wednesday. They set a "hold" rating for the company.December 4, 2024 | marketbeat.comWalleye Capital LLC Reduces Position in Revance Therapeutics, Inc. (NASDAQ:RVNC)Walleye Capital LLC decreased its position in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) by 83.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 699,621 shares of the biopharmaceuticaDecember 3, 2024 | marketbeat.comRevance Therapeutics, Crown Labs Extend Tender Offer Start Deadline to Dec. 3 >RVNCNovember 29, 2024 | marketwatch.comHyaluronic Acid Market Report 2024, Featuring Profiles of Allergan, Galderma, Revance Therapeutics, Hyaluronic Acid Manufacturing Co. and Fidia Farmaceutici - Forecasts to 2029November 29, 2024 | globenewswire.comRevance Therapeutics gains as Crown Labs further extends tender offerNovember 21, 2024 | msn.comAlpine Associates Management Inc. Takes Position in Revance Therapeutics, Inc. (NASDAQ:RVNC)Alpine Associates Management Inc. acquired a new stake in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 4,162,861 shares of the biopharmaceutical companyNovember 20, 2024 | marketbeat.comBarclays Remains a Hold on Revance Therapeutics (RVNC)November 19, 2024 | markets.businessinsider.comLMR Partners LLP Acquires New Shares in Revance Therapeutics, Inc. (NASDAQ:RVNC)LMR Partners LLP acquired a new stake in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 2,244,400 shares of the biopharmaceutical compNovember 18, 2024 | marketbeat.comRevance Therapeutics (NASDAQ:RVNC) Coverage Initiated by Analysts at StockNews.comStockNews.com initiated coverage on shares of Revance Therapeutics in a research report on Monday. They set a "hold" rating for the company.November 18, 2024 | marketbeat.comRevance Therapeutics jumps after Crown Laboratories tender offer extended againNovember 13, 2024 | msn.comCautious Hold Rating on Revance Therapeutics Amid Ongoing Merger Uncertainties with Crown LaboratoriesNovember 13, 2024 | markets.businessinsider.comStifel Nicolaus Remains a Hold on Revance Therapeutics (RVNC)November 12, 2024 | markets.businessinsider.comRevance Therapeutics, Inc. (NASDAQ:RVNC) Receives Consensus Rating of "Hold" from AnalystsRevance Therapeutics, Inc. (NASDAQ:RVNC - Get Free Report) has been given an average rating of "Hold" by the nine ratings firms that are covering the company, MarketBeat.com reports. Eight research analysts have rated the stock with a hold rating and one has given a buy rating to the company. TheNovember 12, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNCNovember 10, 2024 | prnewswire.comStockNews.com Begins Coverage on Revance Therapeutics (NASDAQ:RVNC)StockNews.com began coverage on shares of Revance Therapeutics in a research report on Sunday. They set a "hold" rating on the stock.November 10, 2024 | marketbeat.comRevance Therapeutics Reports Q3 Growth Amid Merger PlansNovember 9, 2024 | markets.businessinsider.comRevance withdraws previously provided guidanceNovember 8, 2024 | markets.businessinsider.comRevance Therapeutics sinks amid `going concern' disclosureNovember 8, 2024 | seekingalpha.comRevance Therapeutics' (RVNC) "Hold" Rating Reiterated at Needham & Company LLCNeedham & Company LLC restated a "hold" rating on shares of Revance Therapeutics in a research report on Friday.November 8, 2024 | marketbeat.comRevance Therapeutics (NASDAQ:RVNC) Earns "Neutral" Rating from HC WainwrightHC Wainwright restated a "neutral" rating and set a $6.60 price target on shares of Revance Therapeutics in a report on Friday.November 8, 2024 | marketbeat.comRevance Reports Third Quarter 2024 Financial Results, Provides Corporate UpdateNovember 7, 2024 | businesswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNCNovember 2, 2024 | prnewswire.comLost Money on Revance Therapeutics, Inc. (RVNC)? You May Have Been Affected by Fraud - Contact Levi & KorsinskyNovember 1, 2024 | stockhouse.comRevance Therapeutics (NASDAQ:RVNC) Stock, Insider Trading ActivityOctober 29, 2024 | benzinga.comRevance Therapeutics surges after Crown tender offer extended, settles with TeoxaneOctober 29, 2024 | msn.com Get Revance Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter. Email Address AI breakthrough about to upend industry (Ad)Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing. I urge you to watch it now. RVNC Media Mentions By Week RVNC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RVNC News Sentiment▼0.790.60▲Average Medical News Sentiment RVNC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RVNC Articles This Week▼64▲RVNC Articles Average Week Get Revance Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RVNC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies DAWN News Today ARDX News Today SYRE News Today CALT News Today SPRY News Today ANIP News Today SNDX News Today INVA News Today ELVN News Today RCKT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RVNC) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revance Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revance Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RVNC Stock Alerts